Rho kinase as a target for cerebral vascular disorders

References

• 1 Bederson JB, Connolly ES Jr, Batjer HH et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the stroke council, American heart association. Stroke 40(3), 994–1025 (2009).
  MedlineGoogle Scholar
• 2 Schievink WI. Intracranial aneurysms. N. Engl. J. Med. 336(1), 28–40 (1997).
  Medline CASGoogle Scholar
• 3 Campbell PG, Jabbour P, Yadla S, Awad IA. Emerging clinical imaging techniques for cerebral cavernous malformations: a systematic review. Neurosurg. Focus 29(3), E6 (2010).
  MedlineGoogle Scholar
• 4 Gross BA, Du R. Diagnosis and treatment of vascular malformations of the brain. Curr. Treat. Options Neurol. 16(1), 279 (2014).
  MedlineGoogle Scholar
• 5 Wiebers DO, Whisnant JP, Huston J 3rd et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362(9378), 103–110 (2003).
  MedlineGoogle Scholar
• 6 Loirand G, Guérin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 98(3), 322–334 (2006).
  Medline CASGoogle Scholar
• 7 Hall A. Gtp-binding proteins and the regulation of the actin cytoskeleton. Ann. Rev. Cell Biol. 10, 31–54 (1996).
  Google Scholar
• 8 Zlokovic BV. The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2), 178–201 (2008).
  Medline CASGoogle Scholar
• 9 Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence? J. Cereb. Blood Flow Metab. 32(7), 1207–1221 (2012).
  Medline CASGoogle Scholar
• 10 Neuwelt EA, Bauer B, Fahlke C et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci. 12(3), 169–182 (2011).
  Medline CASGoogle Scholar
• 11 Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: how to “open” the blood brain barrier. Curr. Neuropharmacol. 6(3), 179–192 (2008).
  Medline CASGoogle Scholar
• 12 Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV. Potential role of mcp-1 in endothelial cell tight junctionopening': signaling via Rho and Rho kinase. J. Cell Sci. 116(22), 4615–4628 (2003).
  Medline CASGoogle Scholar
• 13 Hartsock A, Nelson WJ. Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton. Biochim. Biophys. Acta 1778(3), 660–669 (2008).
  Medline CASGoogle Scholar
• 14 Hellström M, Gerhardt H, Kalén M et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 153(3), 543–554 (2001).
  Medline CASGoogle Scholar
• 15 Gerhardt H, Wolburg H, Redies C. N‐cadherin mediates pericytic‐endothelial interaction during brain angiogenesis in the chicken. Dev. Dyn. 218(3), 472–479 (2000).
  Medline CASGoogle Scholar
• 16 Dore-Duffy P. Pericytes: pluripotent cells of the blood–brain barrier. Curr. Pharm. Design 14(16), 1581–1593 (2008).
  Medline CASGoogle Scholar
• 17 Rucker HK, Wynder HJ, Thomas WE. Cellular mechanisms of CNS pericytes. Brain Res. Bull. 51(5), 363–369 (2000).
  Medline CASGoogle Scholar
• 18 Matsui T, Amano M, Yamamoto T et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small gtp binding protein Rho. EMBO J. 15(9), 2208–2216 (1996).
  Medline CASGoogle Scholar
• 19 Ishizaki T, Maekawa M, Fujisawa K et al. The small gtp-binding protein Rho binds to and activates a 160 kda ser/thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 15(8), 1885–1893 (1996).
  Medline CASGoogle Scholar
• 20 Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 4(5), 387–398 (2005).
  Medline CASGoogle Scholar
• 21 Shimada H, Rajagopalan LE. Rho kinase-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via nf-κb p65. J. Biol. Chem. 285(17), 12536–12542 (2010).
  Medline CASGoogle Scholar
• 22 Hyun Lee J, Zheng Y, Bornstadt D et al. Selective rock2 inhibition in focal cerebral ischemia. Ann. Clin. Transl. Neurol. 1(1), 2–14 (2014).
  MedlineGoogle Scholar
• 23 Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 4(6), 446–456 (2003).
  Medline CASGoogle Scholar
• 24 Amin E, Dubey BN, Zhang SC et al. Rho-kinase: regulation, (dys)function, and inhibition. Biol. Chem. 394(11), 1399–1410 (2013).
  Medline CASGoogle Scholar
• 25 Kureishi Y, Kobayashi S, Amano M et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J. Biol. Chem. 272(19), 12257–12260 (1997).
  Medline CASGoogle Scholar
• 26 Kawano Y, Fukata Y, Oshiro N et al. Phosphorylation of myosin-binding subunit (mbs) of myosin phosphatase by Rho-kinase in vivo. J. Cell Sci. 147(5), 1023–1038 (1999).
  CASGoogle Scholar
• 27 Velasco G, Armstrong C, Morrice N, Frame S, Cohen P. Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1m at thr850 induces its dissociation from myosin. FEBS Lett. 527(1–3), 101–104 (2002).
  Medline CASGoogle Scholar
• 28 Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 301(2), H287–H296 (2011).
  Medline CASGoogle Scholar
• 29 Katoh K, Kano Y, Amano M, Onishi H, Kaibuchi K, Fujiwara K. Rho-kinase-mediated contraction of isolated stress fibers. J. Cell Sci. 153(3), 569–584 (2001).
  CASGoogle Scholar
• 30 Koyama M, Ito M, Feng J et al. Phosphorylation of cpi-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase. FEBS Lett. 475(3), 197–200 (2000).
  Medline CASGoogle Scholar
• 31 Terry S, Nie M, Matter K, Balda MS. Rho signaling and tight junction functions. Physiology (Bethesda) 25(1), 16–26 (2010).
  Medline CASGoogle Scholar
• 32 Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV. Potential role of mcp-1 in endothelial cell tight junction ‘opening’: signaling via Rho and Rho kinase. J. Cell Sci. 116(Pt 22), 4615–4628 (2003).
  Medline CASGoogle Scholar
• 33 Yamamoto M, Ramirez SH, Sato S et al. Phosphorylation of claudin-5 and occludin by Rho kinase in brain endothelial cells. Am. J. Pathol. 172(2), 521–533 (2008).
  Medline CASGoogle Scholar
• 34 Harris AR, Daeden A, Charras GT. Formation of adherens junctions leads to the emergence of a tissue-level tension in epithelial monolayers. J. Cell Sci. 127(Pt 11), 2507–2517 (2014).
  Medline CASGoogle Scholar
• 35 Sahai E, Marshall CJ. Rock and dia have opposing effects on adherens junctions downstream of Rho. Nat. Cell Biol. 4(6), 408–415 (2002).
  Medline CASGoogle Scholar
• 36 Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E. Fasudil Ischemic Stroke Study G. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 238(1–2), 31–39 (2005).
  Medline CASGoogle Scholar
• 37 Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389(6654), 990–994 (1997).
  Medline CASGoogle Scholar
• 38 Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351(Pt 1), 95–105 (2000).
  Medline CASGoogle Scholar
• 39 Tamura M, Nakao H, Yoshizaki H et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim. Biophys. Acta 1754(1–2), 245–252 (2005).
  Medline CASGoogle Scholar
• 40 Lu Q, Longo FM, Zhou H, Massa SM, Chen YH. Signaling through Rho gtpase pathway as viable drug target. Curr. Med. Chem. 16(11), 1355–1365 (2009).
  Medline CASGoogle Scholar
• 41 Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 98(3), 322–334 (2006).
  Medline CASGoogle Scholar
• 42 Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 301(2), H287–296 (2011).
  Medline CASGoogle Scholar
• 43 Tatsumi E, Yamanaka H, Kobayashi K, Yagi H, Sakagami M, Noguchi K. Rhoa/rock pathway mediates p38 mapk activation and morphological changes downstream of p2y12/13 receptors in spinal microglia in neuropathic pain. Glia 63(2), 216–228 (2014).
  MedlineGoogle Scholar
• 44 Walters CE, Pryce G, Hankey DJ et al. Inhibition of Rho gtpases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J. Immunol. 168(8), 4087–4094 (2002).
  Medline CASGoogle Scholar
• 45 Lehmann M, Fournier AE, Selles-Navarro I et al. Inactivation of the small gtp-binding protein Rho promotes cns axon regeneration. J. Neurosci 19, 7537–7547 (1999).
  Medline CASGoogle Scholar
• 46 Lord-Fontaine S, Yang F, Diep Q et al. Local inhibition of Rho signaling by cell-permeable recombinant protein ba-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J. Neurotrauma 25(11), 1309–1322 (2008).
  MedlineGoogle Scholar
• 47 Lee JH, Zheng Y, Von Bornstadt D et al. Selective rock2 inhibition in focal cerebral ischemia. Ann. Clin. Transl. Neurol. 1(1), 2–14 (2014).
  Medline CASGoogle Scholar
• 48 Mukai Y, Shimokawa H, Matoba T et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 15(6), 1062–1064 (2001).
  Medline CASGoogle Scholar
• 49 Mori-Kawabe M, Tsushima H, Fujimoto S, Tada T, Ito J. Role of Rho/Rho-kinase and no/cgmp signaling pathways in vascular function prior to atherosclerosis. J. Atheroscler. Thromb. 16(6), 722–732 (2009).
  Medline CASGoogle Scholar
• 50 Plummer NW, Zawistowski JS, Marchuk DA. Genetics of cerebral cavernous malformations. Curr. Neurol. Neurosci. Rep. 5(5), 391–396 (2005).
  Medline CASGoogle Scholar
• 51 Al-Holou WN, O'lynnger TM, Pandey AS et al. Natural history and imaging prevalence of cavernous malformations in children and young adults. J. Neurosurg. Pediatr. 9(2), 198–205 (2012).
  MedlineGoogle Scholar
• 52 Del Curling O Jr, Kelly DL Jr, Elster AD, Craven TE. An analysis of the natural history of cavernous angiomas. J. Neurosurg. 75(5), 702–708 (1991).
  MedlineGoogle Scholar
• 53 Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J. Neurosurg. 75(5), 709–714 (1991).
  Medline CASGoogle Scholar
• 54 Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J. Exp. Med. 207(4), 881–896 (2010).
  Medline CASGoogle Scholar
• 55 Morrison L, Akers A. Cerebral Cavernous Malformations, Familial. University of Washington, Seattle WA. (2003).
  Google Scholar
• 56 Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (ccms): evidence for a two-hit mechanism of ccm pathogenesis. Hum. Mol. Genet. 18(5), 919–930 (2009).
  Medline CASGoogle Scholar
• 57 Whitehead KJ, Chan AC, Navankasattusas S et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho gtpases. Nat. Med. 15(2), 177–184 (2009).
  Medline CASGoogle Scholar
• 58 Zawistowski JS, Stalheim L, Uhlik MT et al. Ccm1 and ccm2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum. Mol. Genet. 14(17), 2521–2531 (2005).
  Medline CASGoogle Scholar
• 59 Hilder TL, Malone MH, Bencharit S et al. Proteomic identification of the cerebral cavernous malformation signaling complex. J. Proteome Res. 6(11), 4343–4355 (2007).
  Medline CASGoogle Scholar
• 60 Leblanc GG, Golanov E, Awad IA, Young WL. Biology of vascular malformations of the brain NWC. Biology of vascular malformations of the brain. Stroke 40(12), e694–702 (2009).
  MedlineGoogle Scholar
• 61 Faurobert E, Albiges-Rizo C. Recent insights into cerebral cavernous malformations: a complex jigsaw puzzle under construction. FEBS J. 277(5), 1084–1096 (2010).
  Medline CASGoogle Scholar
• 62 Bergametti F, Denier C, Labauge P et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am. J. Hum. Genet. 76(1), 42–51 (2005).
  Medline CASGoogle Scholar
• 63 Denier C, Labauge P, Brunereau L et al. Clinical features of cerebral cavernous malformations patients with krit1 mutations. Ann. Neurol. 55(2), 213–220 (2004).
  Medline CASGoogle Scholar
• 64 Wong JH, Awad IA, Kim JH. Ultrastructural pathological features of cerebrovascular malformations: a preliminary report. Neurosurgery 46(6), 1454–1459 (2000).
  Medline CASGoogle Scholar
• 65 Clatterbuck RE, Eberhart CG, Crain BJ, Rigamonti D. Ultrastructural and immunocytochemical evidence that an incompetent blood–brain barrier is related to the pathophysiology of cavernous malformations. J. Neurol. Neurosurg. Psychiatry 71(2), 188–192 (2001).
  Medline CASGoogle Scholar
• 66 Tu J, Stoodley MA, Morgan MK, Storer KP. Ultrastructural characteristics of hemorrhagic, nonhemorrhagic, and recurrent cavernous malformations. J. Neurosurg. 103(5), 903–909 (2005).
  MedlineGoogle Scholar
• 67 Tanriover G, Sozen B, Seker A, Kilic T, Gunel M, Demir N. Ultrastructural analysis of vascular features in cerebral cavernous malformations. Clin. Neurol. Neurosurg. 115(4), 438–444 (2013).
  MedlineGoogle Scholar
• 68 Bertalanffy H, Benes L, Miyazawa T, Alberti O, Siegel AM, Sure U. Cerebral cavernomas in the adult. Review of the literature and analysis of 72 surgically treated patients. Neurosurg. Rev. 25(1–2), 1–53; discussion 54–55 (2002).
  MedlineGoogle Scholar
• 69 Ellenbogen R, Abdulrauf S, Sekhar L. Principles Of Neurological Surgery. Elsevier Press, Seattle, WA. (2012).
  Google Scholar
• 70 Amin-Hanjani S, Ogilvy CS, Ojemann RG, Crowell RM. Risks of surgical management for cavernous malformations of the nervous system. Neurosurgery 42(6), 1220–1227; discussion 1227–1228 (1998).
  Medline CASGoogle Scholar
• 71 Moultrie F, Horne MA, Josephson CB et al. Outcome after surgical or conservative management of cerebral cavernous malformations. Neurology 83(7), 582–589 (2014).
  MedlineGoogle Scholar
• 72 Dalyai RT, Ghobrial G, Awad I et al. Management of incidental cavernous malformations: a review. Neurosurg. Focus 31(6), E5 (2011).
  MedlineGoogle Scholar
• 73 Golden M, Saeidi S, Liem B, Marchand E, Morrison L, Hart B. Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiation. J. Med. Imaging Radiat. Oncol. 59(1), 134–136 (2015).
  MedlineGoogle Scholar
• 74 Pham M, Gross BA, Bendok BR, Awad IA, Batjer HH. Radiosurgery for angiographically occult vascular malformations. Neurosurg. Focus 26(5), E16 (2009).
  MedlineGoogle Scholar
• 75 Borikova AL, Dibble CF, Sciaky N et al. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J. Biol. Chem. 285(16), 11760–11764 (2010).
  Medline CASGoogle Scholar
• 76 Crose LE, Hilder TL, Sciaky N, Johnson GL. Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated Rhoa degradation in endothelial cells. J. Biol. Chem. 284(20), 13301–13305 (2009).
  Medline CASGoogle Scholar
• 77 Chen W, Mao K, Liu Z, Dinh-Xuan AT. The role of the Rhoa/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (review). Oncol. Lett. 8(5), 1907–1911 (2014).
  Medline CASGoogle Scholar
• 78 Van Nieuw Amerongen GP, Koolwijk P, Versteilen A, Van Hinsbergh VW. Involvement of Rhoa/Rho kinase signaling in vegf-induced endothelial cell migration and angiogenesis in vitro. Arterioscler. Thromb. Vasc. Biol. 23(2), 211–217 (2003).
  Medline CASGoogle Scholar
• 79 Mei Y, Liao JK. Rho kinase and angiogenesis. Immunol. Endocrine Metabolic Agents in Med. Chem. 14(3), 14–28 (2014).
  Google Scholar
• 80 Glading A, Han J, Stockton RA, Ginsberg MH. Krit-1/ccm1 is a rap1 effector that regulates endothelial cell cell junctions. J. Cell Sci. 179(2), 247–254 (2007).
  CASGoogle Scholar
• 81 Cooper GM. The Cell: A Molecular Approach. Sinauer associates, Sunderland, MA. (2000).
  Google Scholar
• 82 Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 91(4), 1487–1500 (2001).
  Medline CASGoogle Scholar
• 83 Garcia JG, Schaphorst KL. Regulation of endothelial cell gap formation and paracellular permeability. J. Investig. Med. 43(2), 117–126 (1995).
  Medline CASGoogle Scholar
• 84 Kluger MS. 6. Vascular endothelial cell adhesion and signaling during leukocyte recruitment. Adv. Dermatol. 20, 163–164 (2004).
  MedlineGoogle Scholar
• 85 Baumer Y, Burger S, Curry F, Golenhofen N, Drenckhahn D, Waschke J. Differential role of Rho gtpases in endothelial barrier regulation dependent on endothelial cell origin. Histochem. Cell Biol. 129(2), 179–191 (2008).
  Medline CASGoogle Scholar
• 86 Terry S, Nie M, Matter K, Balda MS. Rho signaling and tight junction functions. Physiology 25(1), 16–26 (2010).
  Medline CASGoogle Scholar
• 87 Wojciak-Stothard B, Potempa S, Eichholtz T, Ridley AJ. Rho and rac but not cdc42 regulate endothelial cell permeability. J. Cell Sci. 114(Pt 7), 1343–1355 (2001).
  Medline CASGoogle Scholar
• 88 Smith AL, Dohn MR, Brown MV, Reynolds AB. Association of Rho-associated protein kinase 1 with e-cadherin complexes is mediated by p120-catenin. Mol. Biol. Cell 23(1), 99–110 (2012).
  Medline CASGoogle Scholar
• 89 Mcdonald DA, Shi C, Shenkar R et al. Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the ccm genes: evidence for a common biochemical pathway for ccm pathogenesis. Hum. Mol. Genet. 23(16), 4357–4370 (2014).
  Medline CASGoogle Scholar
• 90 Mcdonald DA, Shi C, Shenkar R et al. Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke 43(2), 571–574 (2012).
  Medline CASGoogle Scholar
• 91 Humphrey JD, Taylor CA. Intracranial and abdominal aortic aneurysms: Similarities, differences, and need for a new class of computational models. Annu. Rev. Biomed. Eng. 10, 221–246 (2008).
  Medline CASGoogle Scholar
• 92 Sekhar LN, Heros RC. Origin, growth, and rupture of saccular aneurysms: A review. Neurosurgery 8(2), 248–260 (1981).
  Medline CASGoogle Scholar
• 93 Stehbens WE. Histopathology of cerebral aneurysms. Arch. Neurol. 8, 272–285 (1963).
  Medline CASGoogle Scholar
• 94 Scanarini M, Mingrino S, Giordano R, Baroni A. Histological and ultrastructural study of intracranial saccular aneurysmal wall. Acta Neurochir. (Wien.) 43(3–4), 171–182 (1978).
  Medline CASGoogle Scholar
• 95 Humphrey J, Taylor C. Intracranial and abdominal aortic aneurysms: Similarities, differences, and need for a new class of computational models. Annu. Rev. Biomed. Eng. 10, 221 (2008).
  Medline CASGoogle Scholar
• 96 Crompton MR. The pathology of ruptured middle-cerebral aneurysms with special reference to the differences between the sexes. Lancet 2(7253), 421–425 (1962).
  Medline CASGoogle Scholar
• 97 Qureshi AI, Suarez JI, Parekh PD et al. Risk factors for multiple intracranial aneurysms. Neurosurgery 43(1), 22–26; discussion 26–27 (1998).
  Medline CASGoogle Scholar
• 98 Rinkel GJ, Djibuti M, Algra A, Van Gijn J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke 29(1), 251–256 (1998).
  Medline CASGoogle Scholar
• 99 Kurki MI, Häkkinen S-K, Frösen J et al. Upregulated signaling pathways in ruptured human saccular intracranial aneurysm wall: an emerging regulative role of toll-like receptor signaling and nuclear factor-κb, hypoxia-inducible factor-1a, and ets transcription factors. Neurosurgery 68(6), 1667–1676 (2011).
  MedlineGoogle Scholar
• 100 Johnston SC, Higashida RT, Barrow DL et al. Recommendations for the endovascular treatment of intracranial aneurysms: a statement for healthcare professionals from the committee on cerebrovascular imaging of the american heart association council on cardiovascular radiology. Stroke 33(10), 2536–2544 (2002).
  MedlineGoogle Scholar
• 101 Alawi A, Edgell RC, Elbabaa SK et al. Treatment of cerebral aneurysms in children: analysis of the kids' inpatient database. J. Neurosurg. Pediatr. 14(1), 23–30 (2014).
  MedlineGoogle Scholar
• 102 Taha MM, Nakahara I, Higashi T et al. Endovascular embolization vs surgical clipping in treatment of cerebral aneurysms: morbidity and mortality with short-term outcome. Surg. Neurol. 66(3), 277–284; discussion 284 (2006).
  MedlineGoogle Scholar
• 103 Mackey J, Brown RD Jr, Moomaw CJ et al. Familial intracranial aneurysms: is anatomic vulnerability heritable? Stroke 44(1), 38–42 (2013).
  MedlineGoogle Scholar
• 104 Broderick JP, Brown RD Jr, Sauerbeck L et al. Greater rupture risk for familial as compared with sporadic unruptured intracranial aneurysms. Stroke 40(6), 1952–1957 (2009).
  MedlineGoogle Scholar
• 105 Stehbens WE. Pathology and pathogenesis of intracranial berry aneurysms. Neurol. Res. 12(1), 29–34 (1990).
  Medline CASGoogle Scholar
• 106 Finlay HM, Whittaker P, Canham PB. Collagen organization in the branching region of human brain arteries. Stroke 29(8), 1595–1601 (1998).
  Medline CASGoogle Scholar
• 107 Inci S, Spetzler RF. Intracranial aneurysms and arterial hypertension: a review and hypothesis. Surg. Neurol. 53(6), 530–540; discussion 540–532 (2000).
  Medline CASGoogle Scholar
• 108 Eldawoody H, Shimizu H, Kimura N et al. Fasudil, a Rho-kinase inhibitor, attenuates induction and progression of cerebral aneurysms: Experimental study in rats using vascular corrosion casts. Neurosci. Lett. 470(1), 76–80 (2010).
  Medline CASGoogle Scholar
• 109 Hashimoto N, Hadna H, Nagata I, Hazama F. (Experimental inducement of saccular cerebral aneuryms in rats [author's transl]). No Shinkei Geka 8(1), 31–34 (1980).
  Medline CASGoogle Scholar
• 110 Hashimoto N, Kim C, Kikuchi H, Kojima M, Kang Y, Hazama F. Experimental induction of cerebral aneurysms in monkeys. J. Neurosurg. 67(6), 903–905 (1987).
  Medline CASGoogle Scholar
• 111 Handa H, Hashimoto N, Nagata I, Hazama F. Saccular cerebral aneurysms in rats: a newly developed animal model of the disease. Stroke 14(6), 857–866 (1983).
  Medline CASGoogle Scholar
• 112 Nagata I, Handa H, Hashimoto N, Hazama F. Experimentally induced cerebral aneurysms in rats: Part VI. Hypertension. Surg. Neurol. 14(6), 477–479 (1980).
  Medline CASGoogle Scholar
• 113 Kondo S, Hashimoto N, Kikuchi H, Hazama F, Nagata I, Kataoka H. Cerebral aneurysms arising at nonbranching sites. An experimental study. Stroke 28(2), 398–403; discussion 403–394 (1997).
  Medline CASGoogle Scholar
• 114 De La Monte SM, Moore GW, Monk MA, Hutchins GM. Risk factors for the development and rupture of intracranial berry aneurysms. Am. J. Med. 78(6 Pt 1), 957–964 (1985).
  Medline CASGoogle Scholar
• 115 Mukai Y, Shimokawa H, Matoba T et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 15(6), 1062–1064 (2001).
  Medline CASGoogle Scholar
• 116 Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389(6654), 990–994 (1997).
  Medline CASGoogle Scholar
• 117 Heissler SM, Manstein DJ. Nonmuscle myosin-2: Mix and match. Cell. Mol. Life Sci. 70(1), 1–21 (2013).
  Medline CASGoogle Scholar
• 118 Kolluru GK, Majumder S, Chatterjee S. Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling. Nitric Oxide 43, 45–54 (2014).
  Medline CASGoogle Scholar
• 119 Peterson EC, Wang Z, Britz G. Regulation of cerebral blood flow. Int. J. Vasc. Med. 2011 823525 (2011).
  MedlineGoogle Scholar
• 120 Willie CK, Tzeng YC, Fisher JA, Ainslie PN. Integrative regulation of human brain blood flow. J. Physiol. 592(Pt 5), 841–859 (2014).
  Medline CASGoogle Scholar
• 121 Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc. Brain Metab. Rev. 2(2), 161–192 (1990).
  Medline CASGoogle Scholar
• 122 Tan CO, Hamner JW, Taylor JA. The role of myogenic mechanisms in human cerebrovascular regulation. J. Physiol. 591(Pt 20), 5095–5105 (2013).
  Medline CASGoogle Scholar
• 123 Gonzalez R, Fernandez-Alfonso MS, Rodriguez-Martinez MA et al. Pressure-induced contraction of the juxtamedullary afferent arterioles in spontaneously hypertensive rats. Gen. Pharmacol. 25(2), 333–339 (1994).
  Medline CASGoogle Scholar
• 124 Harder DR, Roman RJ, Gebremedhin D, Birks EK, Lange AR. A common pathway for regulation of nutritive blood flow to the brain: arterial muscle membrane potential and cytochrome p450 metabolites. Acta Physiol. Scand. 164(4), 527–532 (1998).
  Medline CASGoogle Scholar
• 125 Masumoto N, Tanabe Y, Saito M, Nakayama K. Attenuation of pressure-induced myogenic contraction and tyrosine phosphorylation by fasudil, a cerebral vasodilator, in rat cerebral artery. Br. J. Pharmacol. 130(2), 219–230 (2000).
  Medline CASGoogle Scholar
• 126 Gokina NI, Park KM, Mcelroy-Yaggy K, Osol G. Effects of Rho kinase inhibition on cerebral artery myogenic tone and reactivity. J. Appl. Physiol. 98(5), 1940–1948 (2005).
  Medline CASGoogle Scholar
• 127 Tanweer O, Wilson T, Metaxa E, Riina H, Meng H. E-016 a comparative review of the hemodynamics and pathogenesis of cerebral and abdominal aortic aneurysms: lessons to learn from each other. J. Neurointerv. Surg. 6(Suppl. 1), A45 (2014).
  Google Scholar
• 128 Stehbens WE. Etiology of intracranial berry aneurysms. J. Neurosurg. 70(6), 823–831 (1989).
  Medline CASGoogle Scholar
• 129 Langille BL. Arterial remodeling: relation to hemodynamics. Can. J. Physiol. Pharmacol. 74(7), 834–841 (1996).
  Medline CASGoogle Scholar
• 130 Cebral JR, Vazquez M, Sforza DM et al. Analysis of hemodynamics and wall mechanics at sites of cerebral aneurysm rupture. J. Neurointerv. Surg. doi:10.1136/neurintsurg-2014-011247 (2014)(Epub ahead of print).
  Google Scholar
• 131 Ellegala DB, Day AL. Ruptured cerebral aneurysms. N. Engl. J. Med. 352(2), 121–124 (2005).
  Medline CASGoogle Scholar
• 132 Hashimoto T, Meng H, Young WL. Intracranial aneurysms: links among inflammation, hemodynamics and vascular remodeling. Neurol. Res. 28(4), 372–380 (2006).
  MedlineGoogle Scholar
• 133 Strother CM, Graves VB, Rappe A. Aneurysm hemodynamics: an experimental study. AJNR Am. J. Neuroradiol. 13(4), 1089–1095 (1992).
  Medline CASGoogle Scholar
• 134 Xiang J, Yu J, Choi H et al. Rupture resemblance score (rrs): toward risk stratification of unruptured intracranial aneurysms using hemodynamic-morphological discriminants. J. Neurointerv. Surg. (2014).
  Google Scholar
• 135 Davies PF. Flow-mediated endothelial mechanotransduction. Physiol. Rev. 75(3), 519–560 (1995).
  Medline CASGoogle Scholar
• 136 Shay-Salit A, Shushy M, Wolfovitz E et al. Vegf receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. Proc. Natl Acad. Sci. USA 99(14), 9462–9467 (2002).
  Medline CASGoogle Scholar
• 137 Kano Y, Katoh K, Fujiwara K. Lateral zone of cell-cell adhesion as the major fluid shear stress-related signal transduction site. Circ. Res. 86(4), 425–433 (2000).
  Medline CASGoogle Scholar
• 138 Li S, Chen BP, Azuma N et al. Distinct roles for the small gtpases cdc42 and Rho in endothelial responses to shear stress. J. Clin. Invest. 103(8), 1141–1150 (1999).
  Medline CASGoogle Scholar
• 139 Tzima E. Role of small gtpases in endothelial cytoskeletal dynamics and the shear stress response. Circ. Res. 98(2), 176–185 (2006).
  Medline CASGoogle Scholar
• 140 Van Der Meel R, Symons MH, Kudernatsch R et al. The vegf/Rho gtpase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug Discov. Today 16(5–6), 219–228 (2011).
  Medline CASGoogle Scholar
• 141 Hoang MV, Whelan MC, Senger DR. Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc. Natl Acad. Sci. USA 101(7), 1874–1879 (2004).
  Medline CASGoogle Scholar
• 142 Li F, Xia W, Li A, Zhao C, Sun R. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. Pharmacol. Res. 55(1), 64–71 (2007).
  Medline CASGoogle Scholar
• 143 Yasuno K, Bilguvar K, Bijlenga P et al. Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat. Genet. 42(5), 420–425 (2010).
  Medline CASGoogle Scholar
• 144 Takahashi M, Ishida T, Traub O, Corson MA, Berk BC. Mechanotransduction in endothelial cells: temporal signaling events in response to shear stress. J. Vasc. Res. 34(3), 212–219 (1997).
  Medline CASGoogle Scholar
• 145 Chyatte D, Bruno G, Desai S, Todor DR. Inflammation and intracranial aneurysms. Neurosurgery 45(5), 1137–1146; discussion 1146–1137 (1999).
  Medline CASGoogle Scholar
• 146 Kataoka K, Taneda M, Asai T, Kinoshita A, Ito M, Kuroda R. Structural fragility and inflammatory response of ruptured cerebral aneurysms. A comparative study between ruptured and unruptured cerebral aneurysms. Stroke 30(7), 1396–1401 (1999).
  Medline CASGoogle Scholar
• 147 Frosen J, Piippo A, Paetau A et al. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke 35(10), 2287–2293 (2004).
  MedlineGoogle Scholar
• 148 Millan J, Ridley AJ. Rho gtpases and leucocyte-induced endothelial remodelling. Biochem. J. 385(Pt 2), 329–337 (2005).
  Medline CASGoogle Scholar
• 149 Newman-Tancredi A, Cussac D, Marini L, Millan MJ. Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-ht1a receptor-mediated gαi3activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. Molec. Pharm. 62(3), 590 (2002).
  Medline CASGoogle Scholar
• 150 Strey A, Janning A, Barth H, Gerke V. Endothelial Rho signaling is required for monocyte transendothelial migration. FEBS Lett. 517(1), 261–266 (2002).
  Medline CASGoogle Scholar
• 151 Zhang W, Zhan X, Gao M et al. Self-assembling peptide nanofiber scaffold enhanced with Rhoa inhibitor ct04 improves axonal regrowth in the transected spinal cord. J. Nanomater. 2012 54 (2012).
  Google Scholar
• 152 Wang YX, Martin-Mcnulty B, Da Cunha V et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin ii-induced abdominal aortic aneurysm in apolipoprotein e-deficient mice by inhibiting apoptosis and proteolysis. Circulation 111(17), 2219–2226 (2005).
  Medline CASGoogle Scholar
• 153 Tsai SH, Huang PH, Peng YJ et al. Zoledronate attenuates angiotensin ii-induced abdominal aortic aneurysm through inactivation of Rho/rock-dependent jnk and nf-kappab pathway. Cardiovasc. Res. 100(3), 501–510 (2013).
  Medline CASGoogle Scholar
• 154 Zhao J, Zhou D, Guo J et al. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. Neurol. Med. Chir. (Tokyo) 51(10), 679–683 (2011).
  MedlineGoogle Scholar
• 155 Shibuya M, Suzuki Y, Sugita K et al. Effect of at877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J. Neurosurg. 76(4), 571–577 (1992).
  Medline CASGoogle Scholar
• 156 Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol. 68(2), 126–131; discussion 131–122 (2007).
  MedlineGoogle Scholar
• 157 Fehlings M, Theodore N, Harrop J et al. A phase i/iia clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J. Neurotrauma 28, 787–796 (2011).
  MedlineGoogle Scholar
• 158 Feng Y, Lograsso PV. Rho kinase inhibitors: a patent review (2012 -2013). Expert Opin. Ther. Pat. 24(3), 295–307 (2014).
  Medline CASGoogle Scholar
• 159 Leysen D, Defert O, Boland S, Al. E. Novel rock inhibitors. Wo 2012146724. (2012).
  Google Scholar
• 160 Allen J, Boland S, Bourin A, Al. E. Novel soft rock inhibitors. Wo 2013030366. (2013).
  Google Scholar
• 161 Allen J, Boland S, Bourin A, Al. E. Novel rock inhibitors. Wo 2013030365. (2013).
  Google Scholar
• 162 Allen J, Boland S, Bourin A, Al. E. Biphenylcarboxamides as rock kinase inhibitors. Wo 2013030367. (2013).
  Google Scholar
• 163 Guan R, Xu X, Chen M et al. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Eur. J. Med. Chem. 70, 613–622 (2013).
  Medline CASGoogle Scholar
• 164 Hou T, Yu H, Shen M, Al. E. Application of compound in preparing anti-tumor medicament. Cn102697782. (2012).
  Google Scholar
• 165 Hou T, Yu H, Shen M, Al. E. Application of 3–4-(sulfonyl)benzene] urea compound to preparation of antitumor medicament. Cn102327275. (2012).
  Google Scholar
• 166 Hou T, Yu H, Shen M, Al. E. 4,7-dihydrotetrazole[1,5-a]pyrimidine derivative and application thereof to preparation of antitumor medicine. Cn102432612. (2012).
  Google Scholar
• 167 Cook BN, Kowalski J, Li X, Al. E. N-cyclyl-3-(cyclylcarbonylaminomethyl) benzamide derivatives as Rho kinase inhibitors. Wo 2012006203. (2012).
  Google Scholar
• 168 Zhang JY, Dong HS, Oqani RK, Lin T, Kang JW, Jin DI. Distinct roles of rock1 and rock2 during development of porcine preimplantation embryos. Reproduction 148(1), 99–107 (2014).
  Medline CASGoogle Scholar
• 169 Montalvo J, Spencer C, Hackathorn A et al. Rock1 & 2 perform overlapping and unique roles in angiogenesis and angiosarcoma tumor progression. Curr. Mol. Med. 13(1), 205–219 (2013).
  Medline CASGoogle Scholar
• 170 Shi J, Wu X, Surma M et al. Distinct roles for rock1 and rock2 in the regulation of cell detachment. Cell Death Dis. 4, e483 (2013).
  Medline CASGoogle Scholar
• 171 Mertsch S, Thanos S. Opposing signaling of rock1 and rock2 determines the switching of substrate specificity and the mode of migration of glioblastoma cells. Mol. Neurobiol. 49(2), 900–915 (2014).
  Medline CASGoogle Scholar
• 172 Mckerracher L, Thouin E, Lubell W, Al. E. 4-substituted piperidine derivatives. Wo03042174. (2005).
  Google Scholar
• 173 Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119(1), 131–138 (2009).
  Medline CASGoogle Scholar
• 174 Nohria A, Prsic A, Liu PY et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205(2), 517–521 (2009).
  Medline CASGoogle Scholar
• 175 Li DY, Whitehead KJ. Evaluating strategies for the treatment of cerebral cavernous malformations. Stroke 41(10 Suppl.), S92–S94 (2010).
  Medline CASGoogle Scholar
• 176 Patterson C. Torturing a blood vessel. Nature medicine 15(2), 137–138 (2009).
  Medline CASGoogle Scholar
• 177 Whitehead KJ, Chan AC, Navankasattusas S et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho gtpases. Nat. Med. 15(2), 177–184 (2009).
  Medline CASGoogle Scholar
• 178 Yoshimura Y, Murakami Y, Saitoh M et al. Statin use and risk of cerebral aneurysm rupture: a hospital-based case-control study in Japan. J. Stroke Cerebrovasc. Dis. 23(2), 343–348 (2014).
  MedlineGoogle Scholar
• 179 Eisa-Beygi S, Wen XY, Macdonald RL. A call for rigorous study of statins in resolution of cerebral cavernous malformation pathology. Stroke 45(6), 1859–1861 (2014).
  MedlineGoogle Scholar